Clarification

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Clarification

A guest editorial in The Cancer Letter stated that “work has halted on ECOG-ACRIN Cancer Research Group’s landmark Tomosynthesis Mammographic Imaging Screening Trial.” (The Cancer Letter, April 10, 2020) The TMIST breast cancer screening trial is not suspended. TMIST formally remains an ongoing study under the NCI and Cancer Trials Support Unit. Active participation at this time is at the discretion of individual sites. Sites are making critical local operational decisions to help manage any potential influx of COVID-19 patients and maintain the safety of patients and staff. As a result, some sites have suspended non-urgent health care services, such as screening mammography, and research operations.

Correction

A COVID-19 Update on April 24 reported that The Association of American Cancer Institutes annual meeting has moved to a virtual format (The Cancer Letter, April 24, 2020). The Association of American Cancer Institutes’ Clinical Research Innovation (CRI) program has moved its July 7-8 annual meeting to a virtual format. The AACI annual meeting, which takes place Oct. 11-13 in Kansas City, MO, is still scheduled as an in-person meeting at this time.

Table of Contents

YOU MAY BE INTERESTED IN

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.
If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login